- Home
- PAYP vs IONS Comparison
PAYP vs IONS Comparison
Compare PAYP & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYP | IONS |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.1B |
| IPO Year | 2025 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PAYP | IONS |
|---|---|---|
| Price | $16.51 | $44.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 22 |
| Target Price | $25.54 | ★ $93.36 |
| AVG Volume (30 Days) | 710.9K | ★ 3.6M |
| Earning Date | 08-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.92 | $77.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.07 | $43.01 |
| 52 Week High | $24.89 | $86.74 |
Technical Indicators
Market Signals| Indicator | PAYP | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 31.17 |
| Support Level | $14.47 | N/A |
| Resistance Level | $18.98 | $78.11 |
| Average True Range (ATR) | 0.75 | 2.46 |
| MACD | -0.20 | -0.73 |
| Stochastic Oscillator | 15.38 | 13.48 |
Price Performance
Historical ComparisonAbout PAYP PayPay Corporation American Depository Shares
PayPay is a financial technology company jointly owned by Softbank and LY. It was founded in 2018, following the success of Alipay and WeChat Pay in China, and was the pioneering code payment app in Japan. Over the past seven years, it has amassed more than 70 million users and is the market leader in code payments.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).